需要重症监护的成人脑膜脑炎临床特征、病因与结局(EURECA):一项国际前瞻性多中心队列研究
EURECA为2017—2020年7国68中心前瞻性国际多中心队列,纳入ICU成人脑膜脑炎(急性脑病GCS≤13、脑脊液细胞增多≥5个/mm³及至少两项附加标准)。589例完成3个月随访,病因以急性细菌性脑膜炎最多(247例,41.9%),不明原因脑炎155例(26.2%)。3个月不良功能结局(mRS 3–6分)298例(50.5%,95%CI 46.6–54.6%),死亡152例(25.8%)。多因素分析中年龄>60岁、免疫抑制、院至ICU>1天、GCS运动评分≤3、偏瘫、呼吸衰竭、心血管衰竭与不良结局独立相关,而ICU入院时使用第三代头孢菌素和阿昔洛韦与更好结局相关。
要点
- 589例ICU成人脑膜脑炎中3个月不良功能结局(mRS 3–6分)298例(50.5%,95%CI 46.6–54.6%),死亡152例(25.8%)。
- 院至ICU入住时间>1天与不良功能结局独立相关(OR 2.02,95%CI 1.44–2.99)。
- ICU入院时GCS运动评分≤3(OR 2.23,95%CI 1.49–3.45)和偏瘫(OR 2.48,95%CI 1.47–4.18)与不良结局独立相关。
- 呼吸衰竭(OR 1.76,95%CI 1.05–2.94)和心血管衰竭(OR 1.72,95%CI 1.07–2.75)与不良结局独立相关。
- ICU入院时使用第三代头孢菌素(OR 0.54,95%CI 0.37–0.78)和阿昔洛韦(OR 0.55,95%CI 0.38–0.80)与更好结局相关。
适用人群与场景
- 2017—2020年7国68个中心ICU收治的成人脑膜脑炎患者。
- 纳入标准:急性起病的脑病,GCS≤13;脑脊液细胞增多≥5个/mm³;且至少具备以下两项:发热、癫痫发作、局灶性神经功能缺损、异常神经影像和/或脑电图。
诊断标准与关键阈值
- 脑膜脑炎定义:急性起病脑病(GCS≤13)加脑脊液细胞增多(≥5个/mm³),并至少满足发热、癫痫发作、局灶性神经功能缺损、异常神经影像和/或脑电图中的两项。
- 主要终点为3个月不良功能结局,定义为改良Rankin量表评分3–6分。
红旗征与不能漏的情况
- GCS运动评分≤3与不良功能结局独立相关(OR 2.23,95%CI 1.49–3.45)。
- 偏瘫与不良功能结局独立相关(OR 2.48,95%CI 1.47–4.18)。
- 呼吸衰竭与不良功能结局独立相关(OR 1.76,95%CI 1.05–2.94)。
- 心血管衰竭与不良功能结局独立相关(OR 1.72,95%CI 1.07–2.75)。
研究设计与关键结果
- 研究类型:前瞻性国际多中心队列研究(2017—2020年),68个中心,7个国家。
- 纳入599例,589例(98.3%)完成3个月随访并纳入分析;共识别591个病因:急性细菌性脑膜炎247例(41.9%);病毒、亚急性细菌或真菌/寄生虫感染所致感染性脑炎140例(23.7%);自身免疫性脑炎38例(6.4%);肿瘤性/中毒性脑炎11例(1.9%);不明原因脑炎155例(26.2%)。
- 主要终点:3个月不良功能结局(mRS 3–6分)298例(50.5%,95%CI 46.6–54.6%),其中死亡152例(25.8%)。
- 多因素分析(按中心分层)与不良功能结局独立相关的因素:年龄>60岁(OR 1.75,95%CI 1.22–2.51)、免疫抑制(OR 1.98,95%CI 1.27–3.08)、院至ICU入住时间>1天(OR 2.02,95%CI 1.44–2.99)、GCS运动评分≤3(OR 2.23,95%CI 1.49–3.45)、偏瘫(OR 2.48,95%CI 1.47–4.18)、呼吸衰竭(OR 1.76,95%CI 1.05–2.94)、心血管衰竭(OR 1.72,95%CI 1.07–2.75)。
- ICU入院时使用第三代头孢菌素(OR 0.54,95%CI 0.37–0.78)和阿昔洛韦(OR 0.55,95%CI 0.38–0.80)与不良功能结局风险降低独立相关。
证据类型、等级与局限
- 证据类型:前瞻性国际多中心队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,可改进的可干预因素包括院至ICU入住时间、早期抗微生物治疗以及入院时对呼吸和心血管并发症的识别。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: We aimed to characterize the outcomes of patients with severe meningoencephalitis requiring intensive care.
METHODS: We conducted a prospective multicenter international cohort study (2017-2020) in 68 centers across 7 countries. Eligible patients were adults admitted to the intensive care unit (ICU) with meningoencephalitis, defined by an acute onset of encephalopathy (Glasgow coma scale (GCS) score [Formula: see text] 13), a cerebrospinal fluid pleocytosis [Formula: see text] 5 cells/mm3, and at least two of the following criteria: fever, seizures, focal neurological deficit, abnormal neuroimaging, and/or electroencephalogram. The primary endpoint was poor functional outcome at 3 months, defined by a score of three to six on the modified Rankin scale. Multivariable analyses stratified on centers investigated ICU admission variables associated with the primary endpoint.
RESULTS: Among 599 patients enrolled, 589 (98.3%) completed the 3-month follow-up and were included. Overall, 591 etiologies were identified in those patients which were categorized into five groups: acute bacterial meningitis (n = 247, 41.9%); infectious encephalitis of viral, subacute bacterial, or fungal/parasitic origin (n = 140, 23.7%); autoimmune encephalitis (n = 38, 6.4%); neoplastic/toxic encephalitis (n = 11, 1.9%); and encephalitis of unknown origin (n = 155, 26.2%). Overall, 298 patients (50.5%, 95% CI 46.6-54.6%) had a poor functional outcome, including 152 deaths (25.8%). Variables independently associated with a poor functional outcome were age > 60 years (OR 1.75, 95% CI 1.22-2.51), immunodepression (OR 1.98, 95% CI 1.27-3.08), time between hospital and ICU admission > 1 day (OR 2.02, 95% CI 1.44-2.99), a motor component on the GCS [Formula: see text] 3 (OR 2.23, 95% CI 1.49-3.45), hemiparesis/hemiplegia (OR 2.48, 95% CI 1.47-4.18), respiratory failure (OR 1.76, 95% CI 1.05-2.94), and cardiovascular failure (OR 1.72, 95% CI 1.07-2.75). In contrast, administration of a third-generation cephalosporin (OR 0.54, 95% CI 0.37-0.78) and acyclovir (OR 0.55, 95% CI 0.38-0.80) on ICU admission were protective.
CONCLUSION: Meningoencephalitis is a severe neurologic syndrome associated with high mortality and disability rates at 3 months. Actionable factors for which improvement could be made include time from hospital to ICU admission, early antimicrobial therapy, and detection of respiratory and cardiovascular complications at admission.
参考来源
- Sonneville R, de Montmollin E, Contou D, et al. Clinical features, etiologies, and outcomes in adult patients with meningoencephalitis requiring intensive care (EURECA): an international prospective multicenter cohort study. Intensive Care Med. 2023. PMID: 37022378. doi:10.1007/s00134-023-07032-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。